Stockscreener 앱 받기
20.06
2.76%
-0.57
시간 외 거래:
20.00
-0.06
-0.30%
전일 마감가:
$20.63
열려 있는:
$20.96
하루 거래량:
2.85M
Relative Volume:
1.43
시가총액:
$3.38B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
111.44
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-7.98%
1개월 성능:
-15.71%
6개월 성능:
+42.17%
1년 성능:
+37.87%
1일 변동 폭
$20.02
$20.96
1주일 범위
$20.02
$21.95
52주 변동 폭
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
20.06 | 3.48B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Why ACADIA Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & Safe Entry Zone Identification - newser.com
Leerink Partnrs Issues Optimistic Outlook for ACAD Earnings - MarketBeat
Heatmap analysis for ACADIA Pharmaceuticals Inc. and competitors2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
How high can ACADIA Pharmaceuticals Inc. stock go2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Detecting support and resistance levels for ACADIA Pharmaceuticals Inc.2025 Macro Impact & Verified Momentum Watchlists - newser.com
Applying Elliott Wave Theory to ACADIA Pharmaceuticals Inc.IPO Watch & Expert Curated Trade Ideas - newser.com
Using Bollinger Bands to evaluate ACADIA Pharmaceuticals Inc.July 2025 Momentum & AI Enhanced Execution Alerts - newser.com
How to track smart money flows in ACADIA Pharmaceuticals Inc.July 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
Q3 EPS Estimate for ACADIA Pharmaceuticals Cut by Analyst - MarketBeat
RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating - MarketScreener
Acadia Healthcare Company, Inc. Announces Chief Financial Officer Changes, Effective October 27, 2025 - MarketScreener
What drives ACADIA Pharmaceuticals Inc stock priceHead and Shoulders Patterns & Double Digit Capital Growth - earlytimes.in
How to interpret RSI for ACADIA Pharmaceuticals Inc. stockWeekly Risk Summary & Reliable Intraday Trade Alerts - newser.com
Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Volume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AI2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) - Seeking Alpha
Is ACADIA Pharmaceuticals Inc. stock attractive after correctionRate Hike & Weekly High Conviction Ideas - newser.com
Wealth Enhancement Advisory Services LLC Makes New $511,000 Investment in ACADIA Pharmaceuticals Inc. $ACAD - Defense World
Intraday pattern recognizer results for ACADIA Pharmaceuticals Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWall Street Watch & Reliable Intraday Trade Alerts - newser.com
News impact scoring models applied to ACADIA Pharmaceuticals Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
What machine learning models say about ACADIA Pharmaceuticals Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. rebound enough to break even2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
ACADIA Pharmaceuticals Inc. Securities Lawsuit Investigation - Claim Depot
Using flow based indicators on ACADIA Pharmaceuticals Inc.Weekly Loss Report & High Conviction Trade Alerts - newser.com
A Look at Acadia Pharmaceuticals’s Valuation After Setback in Phase 3 Prader-Willi Trial - Sahm
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - BioSpace
Published on: 2025-10-03 03:21:29 - newser.com
Acadia to present pipeline updates at Parkinson’s congress By Investing.com - Investing.com Nigeria
Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions - Fierce Pharma
Acadia to present pipeline updates at Parkinson’s congress - Investing.com
Upcoming Events - FinancialContent
ATTENTION ACADIA Pharmaceuticals Inc. (ACAD) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial - MSN
Published on: 2025-10-01 09:39:16 - newser.com
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acadia Pharmaceuticals Inc 주식 (ACAD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director |
Sep 02 '25 |
Sale |
25.98 |
1,600 |
41,560 |
25,382 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 18 '25 |
Sale |
25.18 |
22,000 |
554,024 |
40,130 |
5.74%
자본화:
|
볼륨(24시간):